One-year clinical trial data for the next-generation, investigational, Sphere-360TM single-shot PFA catheter show impressive safety, perf ...

Abbott has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months for patients receiving pulsed field ablation (PFA) therapy with the Volttm PFA System ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical outcomes from two studies in atrial fibrillation (AFib) patients treated with the Affera™ family ...

Abbott (NYSE: ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months ...

Another benefit of GLP-1 receptor agonist (RA) use may be protection from persistent atrial fibrillation (Afib or AF) after ...

Persistent Systems Ltd., incorporated in the year 1990, is a Mid Cap company (having a market cap of Rs 80,473.15 Crore) operating in IT Software sector. Persistent Systems Ltd. key Products/Revenue ...

PFA is a newer Afib ablation modality touted as reducing the risk of damaging nearby collateral structures, compared with ...

Patients with a high probability of HFpEF may experience greater benefits from atrial fibrillation ablation than those with a ...

Barclays analyst Matt Miksic raised the firm’s price target on Boston Scientific (BSX) to $125 from $118 and keeps an Overweight rating on the ...

Boston Scientific’s FARAPULSE system is showing some serious promise in zapping away persistent atrial fibrillation, ...

Boston Scientific Corporation today announced positive 12-month primary endpoint results from the second phase of the ...

Boston Scientific (BSX) announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial ...